#Lanadelumab
LightNews LightNews
annalsacaai.bsky.social
One of the first-line options for long term prophylaxis in HAE patients is lanadelumab, a fully human monoclonal antibody inhibiting plasma kallikrein. The authors report findings from 2 prospective, noninterventional, multicenter phase 4 studies. Learn more: https://loom.ly/gMx757w
November 18, 2025 at 8:10 PM
journal-cer.bsky.social
📢New article alert

New study in JCER compares lanadelumab vs C1-esterase inhibitors in pediatric #HAE patients.

🔗Read here: becarispublishing.com/doi/10.57264...

#RareDiseases #HereditaryAngioedema #OpenAccess #JCER
Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema
Aim: To compare the efficacy and safety of lanadelumab versus other approved long-term prophylaxis (LTP) treatments in patients with pediatric hereditary angioedema (HAE) aged <12 years. Mater...
becarispublishing.com
January 28, 2025 at 1:49 PM
newsen.bsky.social
European Medicines Agency Approves New Administration Route for TAKHZYRO® in HAE Patients#None#Takeda#TAKHZYRO#lanadelumab
European Medicines Agency Approves New Administration Route for TAKHZYRO® in HAE Patients
TAKEDA’s TAKHZYRO® (lanadelumab) gains EMA approval for a new subcutaneous pen option for HAE patients aged 12 and older, enhancing treatment accessibility.
third-news.com
February 24, 2025 at 8:07 AM
journal-cer.bsky.social
📢New article alert

New research compares healthcare costs and resource use in HAE patients on lanadelumab vs berotralstat.

🔗Read here: becarispublishing.com/doi/10.57264...

#HereditaryAngioedema #HAE #CostEffectiveness #OpenAccess #JCER
February 25, 2025 at 2:10 PM
scienceopen.bsky.social
'Evolution of Treatments for Hereditary Angioedema in Italy: Use of Lanadelumab in Clinical Practice' - an @aboutscience.bsky.social publication on #ScienceOpen:

🔎 www.scienceopen.com/document?vid...

🖇️ #HereditaryAngioedema #Lanadelumab #RareDiseases #ClinicalPharmacology #ItalyHealthcare
Evolution of Treatments for Hereditary Angioedema in Italy: Use of Lanadelumab in Clinical Practice
<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d10778704e83">Introduction: Hereditary angioedema (HEA) is a rare genetic disorder characterised by re...
www.scienceopen.com
July 10, 2025 at 12:16 PM
newsen.bsky.social
New Subcutaneous Administration for TAKHZYRO® Approved by EMA for HAE Patients#None#Takeda#TAKHZYRO#lanadelumab
New Subcutaneous Administration for TAKHZYRO® Approved by EMA for HAE Patients
The European Medicines Agency has approved a new subcutaneous dosage option for TAKHZYRO®, enhancing treatment for hereditary angioedema patients aged 12 and above.
third-news.com
February 24, 2025 at 8:08 AM
newsen.bsky.social
European Medicines Agency Approves New Subcutaneous Delivery Option for TAKHZYRO®#Spain#Zurich#Takeda#TAKHZYRO#lanadelumab
European Medicines Agency Approves New Subcutaneous Delivery Option for TAKHZYRO®
The EMA has greenlighted a new subcutaneous option for TAKHZYRO® aimed at adolescents and adults, enhancing treatment accessibility for hereditary angioedema patients.
third-news.com
February 24, 2025 at 8:08 AM
newsen.bsky.social
European Medicines Agency Approves New TAKHZYRO® Delivery Option for HAE Patients#Germany#Zurich#HAE#TAKHZYRO#lanadelumab
European Medicines Agency Approves New TAKHZYRO® Delivery Option for HAE Patients
The EMA has approved an additional subcutaneous delivery option for TAKHZYRO®, enhancing treatment for HAE patients aged 12 and older. This innovation aims to improve patient quality of life.
third-news.com
February 24, 2025 at 8:07 AM
angioedemanews.bsky.social
Read More: https://bit.ly/42sV5gZ

New research confirms that Takhzyro gives patients fewer, less severe swelling attacks and a better quality of life, even after 3+ years on treatment.

Managing HAE is about hope and progress every day.
Text on a blue background reads: "Did you know? Takhzyro treatment for 3 years led to fewer, less severe attacks." By AngioedemaNews.com Text: "Hereditary Angioedema (HAE) patients who took Takhzyro (lanadelumab-flyo) for at least three years saw reductions in the frequency and severity of attacks and found that their quality of life improved, data from a U.S. study showed." By AngioedemaNews.com Text promoting Takhzyro treatments, with a "Link in Bio" button and logo for Angioedema News, a BioNews brand. By AngioedemaNews.com
September 22, 2025 at 2:02 PM
l2plabs.bsky.social
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary…
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized…
dlvr.it
February 24, 2025 at 8:37 AM
l2plabs.bsky.social
L'Agence européenne des médicaments (EMA) a approuvé une option supplémentaire d'administration sous-cutanée pour TAKHZYRO® (lanadelumab) chez les patients âgés de 12 ans et plus souffrant d'attaques…
La solution injectable TAKHZYRO en stylo prérempli de 2 ml est maintenant approuvée pour faciliter l'administration sous-cutanée chez les adolescents (âgés de 12 ans et plus) et les adultes atteints d'AOH.1 L'option de stylo prérempli est conçue pour…
dlvr.it
February 24, 2025 at 8:37 AM
l2plabs.bsky.social
Die Europäische Arzneimittelagentur (EMA) hat eine zusätzliche Option zur subkutanen Verabreichung von TAKHZYRO® (Lanadelumab) für Patienten ab 12 Jahren mit wiederkehrenden Attacken des hereditären…
TAKHZYRO-Injektionslösung in einem 2-ml-Fertigpen ist jetzt zur Erleichterung der subkutanen Verabreichung bei jugendlichen (ab 12 Jahren) und erwachsenen Patienten mit HAE zugelassen.1 Die Option des vorgefüllten Pens wurde entwickelt, um eine…
dlvr.it
February 24, 2025 at 8:37 AM
l2plabs.bsky.social
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary…
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized…
dlvr.it
February 24, 2025 at 8:37 AM
l2plabs.bsky.social
La Agencia Europea de Medicamentos aprueba una opción adicional de administración subcutánea de TAKHZYRO®
La Agencia Europea de Medicamentos (EMA) ha aprobado una opción adicional de administración subcutánea de TAKHZYRO® (lanadelumab) para pacientes de 12 años o más con ataques recurrentes de angioedema hereditario (AEH) La solución inyectable TAKHZYRO en…
dlvr.it
February 24, 2025 at 8:37 AM
solnatamd.medsky.social
Thus anti-cytokine storm drugs are out.
New drug targets are in: bradykinin, kallikrein (icatibant, lanadelumab).
While we gather data we should remember to keep patients dry, normoglycemic etc as fluids, sugars destroy already damaged...
December 1, 2024 at 8:14 AM